<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04392622</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-51656</org_study_id>
    <secondary_id>IRB-51656</secondary_id>
    <secondary_id>ENT0072</secondary_id>
    <nct_id>NCT04392622</nct_id>
  </id_info>
  <brief_title>d-Limonene +Radiation +PlatinumBasedChemo for Xerostomia Prevention in LocallyAdvanced HNSCC</brief_title>
  <official_title>A Phase 1 Study of d Limonene With Concurrent Radiation and Platinum Based Chemotherapy for Xerostomia Prevention in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study explores the safety of d-limonene, a commercially-available dietary supplement
      (food) as a potential therapeutic for the severe dry mouth (xerostomia) experienced by
      patients with head and neck cancer as a side effect of their anti-cancer treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:To determine the maximum tolerated dose (MTD) of d limonene when combined
      with radiation and platinum based chemotherapy in subjects with loco regionally advanced head
      and neck squamous cell carcinoma (HNSCC) based upon dose limiting toxicity (DLT)

      Secondary Objective:

        -  To evaluate the feasibility and subject compliance with adjuvant administration of d
           limonene daily up to a maximum of 4 months after completion of chemoradiation

        -  To correlate the level of d-limonene measured in the plasma to the dose levels(s)
           administered to the subject

        -  To correlate the level of d limonene measured in the plasma to saliva flow rate and
           xerostomia questionnaire scores in subjects enrolled in this trial
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting Toxicity</measure>
    <time_frame>9 weeks</time_frame>
    <description>Dose limiting toxicity is defined as d limonene related toxicity causing:
Greater than 1 week delay in completing the radiation course.
Inability to receive ≥ 66 Gy of radiotherapy.
Inability to receive at least 200 mg/m2 of total cisplatin equivalent dose or a total area under the curve (AUC) of 10 for carboplatin equivalent dose due to toxicity related to d-limonene Grade 3 or higher diarrhea that is attributable to the study drug.
Grade 3 abdominal pain that is attributable to the study drug. The outcome will be reported as the number of participants per dose level who experience any DLT (a number without dispersion / variance).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility of adjuvant d-limonene administration</measure>
    <time_frame>4 months</time_frame>
    <description>Participant compliance with adjuvant administration of d-limonene will be assessed as completing at least 14 weeks of per protocol adjuvant d-limonene treatment. The outcome is reported as the number of participants per dose level that were compliant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Xerostomia toxicity</measure>
    <time_frame>12 months post completion of chemoradiation</time_frame>
    <description>The degree of xerostomia will be assessed by the xerostomia survey. The survey consists of 8 items: 4 items regarding dryness or discomfort while eating or chewing and 4 items regarding dryness and discomfort while not eating or chewing. The participant will rate each item on a Likert scale from 0 to 10 (least effect to most severe effect) with higher scores implying greater dryness or discomfort. A summary score is calculated by summing the scores for each item and linearly transforming the score to produce a final score on a scale from 0 to 100. The outcome is reported as the mean and standard deviation of the final transformed scores from all subjects with survey results, by treatment level.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Xerostomia</condition>
  <arm_group>
    <arm_group_label>d-limonene -2gram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 gram d-limonene orally, once daily delivered during chemoradiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>d-limonene -4gram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 gram d-limonene orally, as 2 grams 2 times daily delivered during chemoradiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>d-limonene -6gram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 gram d-limonene orally, as 3 grams 2 times daily delivered during chemoradiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>d-limonene -8gram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 gram d-limonene orally, as 4 grams 2 times daily delivered during chemoradiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>de-escalation dose d-limonene -6gram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 gram d-limonene orally, as 3 grams 2 times daily delivered during chemoradiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>de-escalation dose d-limonene -4gram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 gram d-limonene orally, as 2 grams 2 times daily delivered during chemoradiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>de-escalation dose d-limonene -2gram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 gram d-limonene orally, once daily delivered during chemoradiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D Limonene</intervention_name>
    <description>Administered orally at 2 to 8 grams daily</description>
    <arm_group_label>d-limonene -2gram</arm_group_label>
    <arm_group_label>d-limonene -4gram</arm_group_label>
    <arm_group_label>d-limonene -6gram</arm_group_label>
    <arm_group_label>d-limonene -8gram</arm_group_label>
    <arm_group_label>de-escalation dose d-limonene -2gram</arm_group_label>
    <arm_group_label>de-escalation dose d-limonene -4gram</arm_group_label>
    <arm_group_label>de-escalation dose d-limonene -6gram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity modulated radiotherapy (IMRT)</intervention_name>
    <description>Standard of Care -All patients will receive standard radiation treatment of 66 to 70 Gy given in 33 to 35 fractions (2 to 2.12 Gy/fractions) over 6.5 to 7 weeks.</description>
    <arm_group_label>d-limonene -2gram</arm_group_label>
    <arm_group_label>d-limonene -4gram</arm_group_label>
    <arm_group_label>d-limonene -6gram</arm_group_label>
    <arm_group_label>d-limonene -8gram</arm_group_label>
    <arm_group_label>de-escalation dose d-limonene -2gram</arm_group_label>
    <arm_group_label>de-escalation dose d-limonene -4gram</arm_group_label>
    <arm_group_label>de-escalation dose d-limonene -6gram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Standard of Care -Cisplatin as 100 mg/m2 IV</description>
    <arm_group_label>d-limonene -2gram</arm_group_label>
    <arm_group_label>d-limonene -4gram</arm_group_label>
    <arm_group_label>d-limonene -6gram</arm_group_label>
    <arm_group_label>d-limonene -8gram</arm_group_label>
    <arm_group_label>de-escalation dose d-limonene -2gram</arm_group_label>
    <arm_group_label>de-escalation dose d-limonene -4gram</arm_group_label>
    <arm_group_label>de-escalation dose d-limonene -6gram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Xerostomia questionnaire</intervention_name>
    <description>Xerostomia questionnaire consists of 4 items on dryness while eating/speaking and 4 on dryness at rest. Patients rate each symptom on an 11 point ordinal Likert scale from 0 to 10, with higher scores indicating greater xerostomia</description>
    <arm_group_label>d-limonene -2gram</arm_group_label>
    <arm_group_label>d-limonene -4gram</arm_group_label>
    <arm_group_label>d-limonene -6gram</arm_group_label>
    <arm_group_label>d-limonene -8gram</arm_group_label>
    <arm_group_label>de-escalation dose d-limonene -2gram</arm_group_label>
    <arm_group_label>de-escalation dose d-limonene -4gram</arm_group_label>
    <arm_group_label>de-escalation dose d-limonene -6gram</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of advanced loco regional squamous
             cell carcinoma of the nasopharynx (AJCC v8 Stage II IV); oropharynx (AJCC v8 Stage I
             III for HPV+ cancer, excluding T1 2N0; AJCC v8 Stage III IV for Human papillomavirus
             (HPV) negative cancer); larynx (AJCC v8 Stage III to IV); or hypopharynx (AJCC v8
             Stage III to IV), scheduled to undergo chemoradiation. Patients with squamous cell
             carcinoma of the head and neck from an unknown primary site with involved nodes (N1 to
             3) also qualify.

          -  Scheduled to received definitive RT with concurrent platinum based chemotherapy at
             Stanford

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 1

          -  Must be able to swallow d limonene gelcaps at the time of enrollment.

          -  Adequate hepatic function within 2 weeks prior to registration defined as follows:
             Bilirubin ≤ 2 mg/dL; aspartate aminotransferase (AST) or alanine aminotransferase
             (ALT) &lt; 3 times the upper limit of normal

          -  Adequate hematologic function within 2 weeks prior to registration defined as follows:

               -  Absolute neutrophil count (ANC): ≥ 1,500/mm3

               -  Platelets: ≥ 100,000/mm3

               -  Hemoglobin: ≥ 8.0 g/dL (Note: The use of transfusion or other intervention to
                  achieve Hgb ≥ 8.0 g/dL is acceptable).

          -  Adequate renal function defined as follows:

        Serum creatinine ≤ 1.5 mg/dL within 2 weeks prior to registration or creatinine clearance
        (CC) ≥ 50 mL/min within 2 weeks prior to registration determined by 24 hour collection or
        estimated by Cockcroft Gault formula:

        CCr male = [(140 - age) x (wt in kg)] [(Serum Cr mg/dL) x (72)] CCr female = 0.85 x (CrCl
        male)

          -  Negative serum pregnancy test within 2 weeks prior to registration and agreement to
             use a birth control method during the entire duration of d limonene treatment for
             women of childbearing potential

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  History of allergic reactions attributed to citrus fruits

          -  Pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quynh-Thu Le</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford Universiy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samantha Wong</last_name>
    <phone>650-498-8495</phone>
    <email>swong8@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Samantha Wong</last_name>
      <phone>650-498-8495</phone>
      <email>swong8@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Quynh-Thu Le</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Xerostomia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

